Company Profile For MDS Inc

MDS Inc. (MDS) is a life sciences company that provides products and services to its customers for the development of drugs and the diagnosis and treatment of disease. The Company is a provider of pharmaceutical research services, medical isotopes for molecular imaging, sterilization, radiotherapeutics and analytical instruments. MDS operates in three business units within the life sciences industry: MDS Pharma Services, MDS Nordion and MDS Analytical Technologies. In June 2008, the Company acquired Blueshift Biotechnologies, Inc., a developer of screening platforms for life sciences research. On May 1, 2008 MDS Nordion sold its external beam therapy and self-contained irradiator product lines to Best Medical International Inc. In July 2009, the Company completed the divestiture of its MDS Pharma Services Phase II-IV operations to INC Research, Inc. In November 2009, the Company completed the divestiture of its Central Labs operations to Czura Thornton.

BRIEF: For the nine months ended 31 July 2009, MDS Inc.'s revenues decreased 18% to $630M. Net loss from continuing ops. totaled $53M vs.an income of $24M. Revenues reflects a decrease in products sales, a fall in income from services and lower reimbursement revenues. Net loss also reflects a significant increase in restructuring charges, presence of impairment of goodwill, a fall in interest income and an increase in interest expense.